1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

ElectroCore Brings Next-Gen Vagus Nerve Stimulator To US With Innovative Sales Channel

 
• By Reed Miller

US FDA cleared the gammaCore Sapphire non-invasive vagus nerve stimulator for the acute treatment of pain associated with migraine and episodic cluster headache. Electrocore also recently signed a deal with UpScript to provide a direct-to-patient sales channel for gammaCore.

MT1612_electroCore gammaCore_1200x675
electroCore's gammaCore non-invasive vagus nerve stimulator • Source: gammaCore LLC

electroCore Inc. is ramping up its US commercialization of its gammaCore non-invasive vagus nerve stimulation (NVNS) technology for treatment of acute migraine and episodic cluster headaches.

ElectroCore recently announced the US launch of gammaCore Sapphire, the latest generation of electroCore's unique NVNS therapy. US FDA cleared it in March for the acute treatment of pain associated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.